Workboat Indexes
All News about Genmab A/S ADR
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://mms.businesswire.com/media/20240627569754/en/2172406/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/06/27/AbbVie-Office.png?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20240626204925/en/2171499/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
10 Analysts Assess Genmab: What You Need To Know
June 20, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
What 9 Analyst Ratings Have To Say About Genmab
May 20, 2024
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://investorplace.com/wp-content/uploads/2024/01/arrow-graphic-growth-stocks-1600.jpg)
![](https://mms.businesswire.com/media/20240603640244/en/2146969/22/GenmabLogo.jpg)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via Benzinga
![](https://mms.businesswire.com/media/20240602990089/en/2147628/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/05/24/xrdDAFjtxJSjsw2-j47730601021-t23052308.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20240523620002/en/2138830/22/GenmabLogo.jpg)
Via Chartmill
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://mms.businesswire.com/media/20240601902871/en/2147002/5/Genmab_Logo_Color_RGB.jpg)
![](https://mms.businesswire.com/media/20240521989095/en/2137492/5/Genmab_Logo_Color_RGB.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Analyst Ratings For Genmab
March 26, 2024
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://mms.businesswire.com/media/20240514430927/en/2129709/5/Genmab_Logo_Color_RGB.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://mms.businesswire.com/media/20240422914519/en/2105097/22/GenmabLogo.jpg)
![](https://mms.businesswire.com/media/20240415775924/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://www.investors.com/wp-content/uploads/2024/04/TECH1_radiopharma_042624_shutter.jpg)
![](https://cdn.benzinga.com/files/profoundbio-0408-01.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2024/04/Stock-genmab-01-shutt.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.